Plozasiran, a first-in-class RNA interference therapeutic, reduced triglycerides by 80% and lowered the risk of acute pancreatitis by 83% in patients with familial chylomicronemia syndrome, earning FDA...
A recent phase 3b long-term extension study assessed the safety and efficacy of deucravacitinib over 2 years in patients with moderate-to-severe plaque psoriasis.
A recent phase 3 trial demonstrated that a personalized approach using ibrutinib-venetoclax therapy, based on measurable residual disease, improves progression-free survival and overall survival in patients...
Crinecerfont, a first-in-class therapy, improved androgen control and reduced reliance on high-dose glucocorticoids for patients with congenital adrenal hyperplasia.
In this respiratory disease roundup, researchers report on the efficacy of nirmatrelvir-ritonavir for treating Long COVID, the CDC updates recommendations on “triple threat” vaccines for respiratory virus...
Although more patients are seeking pain relief in primary care settings, practitioners may not have the experience in managing and treating patients with complex pain situations or may not be familiar with...
In a recent retrospective cohort study, researchers examined changes in the medication regimens of patients with type 2 diabetes following the initiation of second-line therapy.
